Ongoing Studies – Actively Recruiting
Atopic Dermatitis
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT05081557
Cat Allergy
A Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home
Study Contact: Susi Snitzler
https://clinicaltrials.gov/ct2/show/NCT04981717
Chronic Spontaneous Urticaria
A Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria (INCEPTION)
Study Contact: Wael Mohammed
https://clinicaltrials.gov/ct2/show/NCT04833855
A randomized, double-blind, placebo-controlled, multi-center, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate to-severe chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment, and who are naïve to omalizumab (RILECSU)
Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT05107115
A Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines (CLOU)
Study Contact: Wael Mohammed
https://clinicaltrials.gov/ct2/show/NCT05032157
Hereditary Angioedema
A Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II) (CHAPTER-1)
Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT05047185
A Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatment of Hereditary Angioedema Type I or II (KVD824)
Study Contact: Leena Johnson Chacko
https://clinicaltrials.gov/ct2/show/NCT05055258
Nasal Polyps
Assessing Long-Term Outcomes of DUPIXENT® Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyposis (AROMA)
Study Contact: Madeleine Smee
https://clinicaltrials.gov/ct2/show/NCT04959448
Peanut Allergy
A 52 week study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy
Study Contact: Susi Snitzler
https://clinicaltrials.gov/ct2/show/NCT04984876
Ongoing Studies – Recruiting Closed
Atopic Dermatitis
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials (ECZTEND)
Cholinergic Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (CINDU)
Eosinophilic Esophagitis
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. (POWER)
Hereditary Angioedema
Study of the long-term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks (CSL312-3002)
Peanut Allergy
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
